EGFR and neoplasm: In a Phase I study (NCT02609776) which included 108 patients with advanced NSCLC, JNJ-61186372 has shown manageable safety profile and broad-spectrum anti-tumor efficacy in patients with EGFR exon 20 insertion, EGFR C797S mutation, MET amplification or resistance to Osimertinib, a third generation EGFR TKI (Park et al. 2020).